文献速递前列腺癌

去势抵抗性前列腺癌中雄激素受体丝氨酸81和213磷酸化研究

Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-05-01

该研究探讨去势抵抗性前列腺癌中雄激素受体丝氨酸81(pARser81)和丝氨酸213(pARser213)磷酸化的表达变化及预后价值。免疫组化显示去势抵抗后pARser81表达降低而pARser213表达升高,高pARser213及两者联合高表达与复发后生存期缩短相关,细胞实验提示恩扎卢胺和BKM120可降低细胞活力。

要点

  • 去势抵抗后pARser81表达降低、pARser213表达升高。
  • 高pARser213及pARser81/pARser213联合高表达与复发后生存期缩短相关。
  • 恩扎卢胺和BKM120均可降低LNCaP-AI细胞活力。

核心结论

  • pARser81与pARser213联合高表达是去势抵抗性前列腺癌的新型预后生物标志物,并可能是预测和治疗靶点。

研究设计与样本

  • 对配对的激素初治和去势抵抗性前列腺癌样本进行免疫组化和免疫荧光检测。
  • 使用DESeq2分析TempO-Seq基因表达谱。
  • LNCaP-AI细胞分别用10 nM DHT或10 nM EGF刺激。
  • 用WST-1法检测10 nM恩扎卢胺和10 nM BKM120对细胞活力的影响。

主要发现

  • 去势抵抗后pARser81表达降低而pARser213表达升高。
  • 去势抵抗样本中pARser81表达与生存无关,但高pARser213表达与复发后生存期缩短相关。
  • pARser81和pARser213联合高表达与复发后生存期缩短相关。
  • LNCaP-AI细胞中10 nM DHT或10 nM EGF诱导pARser81表达,10 nM EGF诱导pARser213表达。
  • 10 nM恩扎卢胺和10 nM BKM120处理后细胞活力降低。

临床怎么用

  • 联合检测pARser81和pARser213或可用于去势抵抗性前列腺癌的预后分层。
  • 靶向雄激素受体和PI3K/AKT信号通路的联合效应尚需进一步研究。

局限性

  • 原文未明确报告样本量。
  • 靶向AR与PI3K/AKT联合效应的结论需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite increases in diagnostics and effective treatments, over 300,000 men die from prostate cancer highlighting the need for specific and differentiating biomarkers. AR phosphorylation associates with castrate-resistance, with pARser213 promoting transcriptional activity. We hypothesise that combined pARser81 and pARser213 reduces survival and would benefit from dual-targeting androgen-dependent and Akt-driven disease. METHODS: Immunohistochemistry and immunofluorescence were performed on matched hormone-naive and castrate-resistant prostate cancer samples. TempO-Seq gene profiling was analysed using DESeq2 package. LNCaP-AI cells were stimulated with DHT or EGF. WST-1 assays were performed to determine effects of Enzalutamide and BKM120 on cell viability. RESULTS: Following the development of castrate-resistance, pARser81 expression reduced and pARser213 expression increased. Castrate-resistance pARser81 expression was not associated with survival but high pARser213 expression was associated with reduced survival from relapse. Combined high pARser81 and pARser213 was associated with reduced survival from relapse. pARser81 expression was induced by 10 nM DHT or 10 nM EGF and pARser213 expression was induced by treatment with 10 nM EGF in LNCaP-AI cells. Cell viability was reduced following treatment with 10 nM Enzalutamide and 10 nM BKM120. Eight genes were differentially expressed between hormone-naive and castrate-resistant tumours and twenty-five genes were differentially expressed between castrate-resistant tumours with high and low pARser213 expression. CONCLUSION: Combined pARser81 and pARser213 provides a novel prognostic biomarker for castrate-resistant disease and a potential predictive and therapeutic target for prostate cancer. Further studies will be required to investigate the combined effects of targeting AR and PI3K/AKT signalling.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. McAllister MJ, McCall P, Dickson A, et al. Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32358577. doi:10.1038/s41391-020-0235-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。